sales and revenue examples, page-12

To a degree Perspicacity. But for as long as both drugs have been in active use there has been a perception (or dogma within the medical community) that combining two opioid is dangerous. MoxDuo is the first ever opioid combination and through a comprehensive PIII trial program have proven that belief wrong. In fact winning the Frost and Sullivan Award for New Product Innovation in 2010 was probably the nail in that coffin for many.

I should also mention i was wrong when i previously posted approval should come in April. I found the PDUFA performance reports on the weekend and the are quite consistent with their adherence to the 6 month timeline. Based on that, if management resubmit the NDA this year we should have an answer in June. Which is what management have been saying for some time.

http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/PDUFA/default.htm

TP, i was thinking about something related just yesterday. Why is it there seems to be very little broker activity on QRX? We get little bits of info from time to time, like what you have posted, but thats all. It seems odd since the top 10 includes HSBC, JPM, CITI, Meryl, UBS et al. I assume its because they are not trying to sell shares so they dont need to advertise the company to retail investors. But thats me being a cynic.